Updates will come soon.................
Saturday, 24 November 2018
Monday, 28 May 2018
Commodity Research Report: Agri Fundamental and Technical report
Highlights: • Agri markets traded with high volatility but failed to take any clear direction as of now. • Good monsoon reports limited the upside while rising export and domestic demand amidst falling arrivals supported the prices at these lower levels after the recent fall. • All eyes are on IMD for further forecasts of sectoral distribution of rains. Any deficiencies in the North-West / Central regions of India could prove bullish for the markets. Also, as the rains reach the Andaman, any declarations by the IMD of Monsoon finally arriving could lead to start of the Monsoon session in the Indian sub-continent. Further price movements will be determined by its progress throughout the rest of India in coming weeks. • Reports of raising MSP (minimum support price) for crops too could lens some support to the prices in the short term.
Zydus Cadila gets USFDA approval to market Nystatin ointment
Zydus Cadila receives final approval to market Nystatin ointment and Omeprazoleand Sodium Bicarbonate capsule, from the US health regulator.
The company received approval to market Nystatin Ointment USP, 1,00,000 units per gram. Nystatin ointment is used to treat fungal infections. It has also received approval to market Omeprazoleand Sodium Bicarbonate Capsules, 20 mg/1100 mg and 40 mg/1100 mg, which is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers).
Further, the drug will be manufactured at the group’s Topical manufacturing facility at Moraiya, Ahemdabad.
Bafna Pharma receives renewal certificate from UK MHRA
Bafna Pharmaceuticals has received renewal certificate, from UK Medicines and Healthcare products Regulatory Agency (MHRA).
The company’s facility, following the audit conducted has got renewal approval as per the guidelines of European Good Manufacturing Practices (EUGMP). Further, the board of directors of the company are scheduled to meet on May 28 to consider the unaudited financial results, for the quarter and the year ended March 31, 2018.
Torrent Pharma issues commercial papers worth Rs.300 crore
Torrent Pharmaceuticals has issued commercial papers worth Rs.300 crore, on May 25,2018.
The board of directors of the company are scheduled to meet on May 30,2018, to consider and approve the audited financial results for the year ended March 31,2018. Further, it will also consider the recommendation of final dividend for the year ended March 31, 2018.
IFFCO, IPL acquires 37% stake in JPMC
IFFCO and Indian Potash Ltd (IPL) have jointly bought 37% stake in Jordan Phosphate Mines Company (JPMC), which is Jordan’s largest mining and chemical firm, for approx Rs.900 crore.
The shares have been purchased from Kamil Holdings, owned by Brunei Investment Agency. IFFCO Managing Director U S Awasthi stated that, IPL has bought about 27%, while IFFCO through its subsidiary Kisan International Trading (KIT) has purchased around 10% in JPMC.
Furthermore, IFFCO already has a joint venture with JPMC in Jordan India Fertilizer Company (JIFCO), in which it has 52% stake, while JPMC holds 48% equity in it.
NTPC Q4 net profit rises 40% at Rs.2,926 crore
NTPC has reported a 40.7% rise in its net profit, for the quarter ended March 31,2018 at Rs.2,926 crore, as against Rs.2,079.4 crore reported in a year ago period.
Revenue of the company rose 13% at Rs.23,100 crore, as against Rs.20,417 crore. EBITDA or the operating profit was up 8.2% at Rs.5,910 crore and margin was at 25.6%. Furthermore,the company’s board has recommended a final dividend of Rs.2.39 per equity share for the financial year 2017-18.
L&T reports 4.7% YoY rise in Q4 profit at Rs.3,167 crore
L&T has reported a 4.69% rise in net profit at Rs.3,167 crore, for the quarter ended March 31,2018.
The company in the corresponding period last year, had reported a profit of Rs.3,025 crore. Consolidated gross revenue for the quarter rose 10% YoY to Rs.40,678 crore. During the quarter under review, the company won fresh orders worth Rs.49,557 crore.
Consolidated order book of the group stood at Rs.2,63,107 crore as of March end, with international order book constituting 24% of the total orders.
UTI MF launches UTI Power of Three
UTI Mutual Fund has launched UTI Power of Three. It is an exercise where an investor can choose to invest a lumpsum or through a SIP in more than one scheme, using a single application form.
The three funds which the UTI Power of Three is focusing are: UTI Mastershare Fund which is an open-ended equity scheme, majorly investing in largecap stocks. UTI Equity Fund is an open-ended equity scheme investing across largecap, midcap and smallcap stocks. UTI Value Opportunities Fund is an open-ended equity scheme following a value investment strategy.
Furthermore, UTI Power of Three is an exercise where the motive is on building one’s core equity portfolio, employing 3 distinct investment styles.
Technical Analysis Of Commodity Market
Technical Analysis Of Commodity Market
Last updated on: May 28, 2018 12:00 AM
Bullions And Its Main Components
| Market Name | Daily Trend | Weekly Trend | Monthly Trend |
| Gold | Buy | Buy | Buy |
| silver | Buy | Buy | Sell |
Base Metals And Its Main Components
| Market Name | Daily Trend | Weekly Trend | Monthly Trend |
| Copper | Sell | Buy | Buy |
| Zinc | Sell | Sell | Buy |
| Lead | Sell | Buy | Buy |
| Nickel | Buy | Buy | Buy |
| Aluminium | Sell | Sell | Buy |
Energy And Its Main Components
| Market Name | Daily Trend | Weekly Trend | Monthly Trend |
| Crude Oil | Sell | Buy | Buy |
| Natural Gas | Buy | Buy | Sell |
BMW unveils updated MINI versions in India
BMW has today launched updated versions of MINI Hatch and MINI Convertible in India, with price ranging between Rs.29.7 lakh and Rs.37.10 lakh (ex-showroom Delhi).
The diesel variant MINI-3 door Cooper D is priced at Rs.29.7 lakh, while the petrol version is price at Rs.33.2 lakh. The diesel-powered MINI-5 door Cooper D is priced at Rs.35 lakh and the MINI Convertible Cooper S is priced at Rs.37.10 lakh. These models will be available at all MINI dealerships as completely built-up (CBU) units, from June onwards.
GAIL posts fourfold rise in Q4 profit at Rs.1,021 crore
GAIL has posted approx fourfold rise in net profit at Rs.1,021 crore, for the quarter ended March 31,2018.
The company in the same quarter last year, had reported a profit of Rs.260 crore. Sales of the company for the quarter under review rose 12.84% to Rs.15,430.69 crore, from Rs.13,674.09 crore in the year ago quarter.
Further, the company’s earnings before interest, tax, depreciation and amortization came in at Rs.1,695 crore and margins for the quarter came in at 11%.
NCC Q4 profit rises 61% to Rs.103 crore
NCC’s net profit during the quarter rose by 61.2% to Rs.102.7 crore, as against a profit of Rs.63.7 crore in the corresponding period last fiscal year.
Revenue from operations increased 11.9% YoY to Rs.2,395 crore for the quarter ended March 2018. EBITDA went up 74.8% to Rs.304.4 crore and margin expanded 460 basis points to 12.7%, compared to year ago period.
Further, the company during the year on standalone basis, secured order of Rs.23,226 crore and the order book of company stood at Rs.30,026 crore as of March 2018, which is 95% more than the previous year.
UBL Q4 net profit rises over 13-fold to Rs.90.88 crore
United Breweries Ltd (UBL) has posted over 13-fold rise in its standalone net profit at Rs.90.88 crore, for the quarter ended March 31,2018.
The company in the year-ago period had posted a net-profit of Rs.6.73 crore. Its total income during the March quarter was up 27.84% to Rs.3,275.38 crore, while in the same quarter last fiscal its total income was at Rs.2,562.03 crore.
Net revenue grew 32% and its total expenses during the quarter came in at Rs.3,138.56 crore, as against Rs.2,554.41 crore during the year ago period.
PNC Infratech secures a project worth Rs.1,738 crore
PNC Infratech has secured a project worth Rs.1,738 crore.
The company has emerged as the lowest bidder for the 42.7 km long 4th package of Lucknow-Ghazipur six lane access controlled Purvanchal expressway project, from Siddhi Ganeshpur to Sansarpur (District Sultanpur) in Uttar Pradesh, on EPC basis for a value of Rs.1,738.44 crore. The construction period for the project is 30 months.
Furthermore, the company has reported a net profit of Rs.111.52 crore, during the quarter ended March 31,2018 and its board of directors has approved a final dividend of 25% per equity share of face value of Rs.2 each, for the financial year ended March 31, 2018.
L&T Construction secures Rs.3,191 crore order for Dhaka Metro
L&T Construction has secured Rs.3,191 crore order from Dhaka Mass Transit Company.
The company has secured the order in joint venture with Marubeni Corporation (Japan), via an international competitive bidding process and the order bagged is for constitutions of a railway line for Dhaka Metro.
In a BSE filing the company stated, “The railways strategic business group of L&T Construction’s transportation infrastructure business has won a major design and build order from the Dhaka Mass Transit Company (DMTC) worth Rs.3,191 crore for electrical and mechanical systems package of Dhaka Mass Rapid Transit Development Project (MRT – line 6).”
Gayatri Projects receives LoA for project worth Rs.425 crore
Gayatri Projects has received letter of award (LoA), from the Ministry of Road Transport and Highways.
The LoA is for part construction of six lane elevated corridor, of NH-163 to de-congest the urban limits of Hyderabad-Bhopalpatnam Section, on EPC basis in Telangana and it is in joint venture with OJSC ‘SIBMOST’.
Further, the board of directors of the company is scheduled to meet on May 30,2018, to consider and approve the audited financial results for the quarter and year ended March 31, 2018.
Cox & Kings subsidiary receives NBFC license from RBI
Cox & Kings subsidiary has received non-banking finance company (NBFC) license, from the Reserve Bank of India (RBI).
The company stated, “Reserve Bank of India (RBI) has granted a non-banking finance company (NBFC) Licence to Cox & Kings Financial Service Limited, a wholly owned Subsidiary of the company.”
Cox & Kings Financial Service Limited plans to carry on the business of holiday financing, student loan financing and other non-banking financial service activities and a foreign exchange business.
Cadila gets USFDA approval to market drug for prostate condition
Zydus Cadila has received final approval from the US health regulator to market Dutasteride and Tamsulosin Hydrochloride capsules.
It is used to treat symptoms of Benign Prostatic Hyperplasia (BPH)-also called prostate gland enlargement. The approval has been granted for the strengths of 0.5 mg/0.4 mg and the drug will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahemdabad.
Further, the group has more than 190 approvals and has so far filed above 320 abbreviated new drug applications (ANDAs), since it started filing in 2003-04.
Lupin’s biosimilar Etanercept accepted for review, by EMA
Lupin’s marketing authorization application (MAA) for biosimilar Etanercept has been accepted for review by Europe drug regulator, European Medicines Agency (EMA).
MAA means an application submitted by a drug manufacturer seeking permission, from the regulator to sell the drug. Etanercept is suggested for treating Rheumatoid Arthritis (RA), Psoriatic Arthritis, Ankylosing Spondylitis, Axial spondyloarthritis, Non-radiographic axial spondyloarthritis and Plaque Psoriasis.
Furthermore, Lupin’s MD Nilesh Gupta stated, “The application for our Etanercept biosimilar and its acceptance in Europe is a significant milestone for our foray into biosimilars in key developed markets. This is also an encouraging development as we continue building our pipeline of higher complexity products.”
Subscribe to:
Posts (Atom)